Feedback / Questions
camidanlumab tesirine (ADCT-301) - Genmab, ADC Therapeutics
https://www.onclive.com/view/camidanlumab-tesirine-plus-pembrolizumab-produces-responses-but-increases-immune-toxicities-in-select-solid-tumors
Jan 9, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next